Quick Answer
Rani Therapeutics Holdings, Inc. reported Operating Income of -$38.31 million for fiscal year 2025.
Rani Therapeutics Holdings, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$38.31M | +28.1% |
| 2024 | -$53.31M | +19.3% |
| 2023 | -$66.10M | -4.2% |
| 2022 | -$63.45M | -23.0% |
| 2021 | -$51.60M | -211.9% |
| 2020 | -$16.54M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$7.26M | +38.5% | +30.9% |
| June 30, 2025 | -$10.51M | +16.1% | +12.6% |
| March 31, 2025 | -$12.01M | +14.4% | -1.8% |
| September 30, 2024 | -$11.80M | +33.9% | +5.8% |
| June 30, 2024 | -$12.52M | +31.5% | +10.8% |
| March 31, 2024 | -$14.03M | +15.0% | +21.4% |
| September 30, 2023 | -$17.86M | -9.3% | +2.4% |
| June 30, 2023 | -$18.29M | -15.4% | -10.8% |
- Rani Therapeutics Holdings, Inc. showed an increase of +28.1% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Rani Therapeutics Holdings, Inc.’s operating income has declined by 131.6% (from -$16.54 million to -$38.31 million).
- The most recent figure is from Rani Therapeutics Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: